Lipid, carbohydrate metabolism, and antioxidant status in children after liver transplantation.
Organ transplantation is a risk factor for atherogenesis that may be related to immunosuppressive therapy. Increased free radical generation may even aggravate atherogenesis. The aim of the study was to assess lipid metabolism in relation to risk factors for atherogenesis as well as carbohydrate metabolism and antioxidant status among children after liver transplantation. We studied 35 children at 3 to 5 years after liver transplant in whom the following parameters were assessed: total cholesterol; triglyceride; high-density lipoprotein cholesterol; low-density lipoprotein cholesterol (LDL-C); very low-density lipoprotein cholesterol; apolipoproteins B, AI, E, lipoprotein (a); vitamin E; glutathione; glucose; insulin; and glutathione peroxidase activity. Three subgroups of patients were assessed according to the immunosuppressive therapy: cyclosporine (CsA), tacrolimus (Tac), or mycophenolate mofetil (MMF) in combination with low-dose CsA or Tac. We observed differences among the subgroups only in total cholesterol (CsA: 131.6 to 285.6; Tac: 144.0 to 181.61; MMF: 132.1 to 181.2) and LDL-C (CsA: 79.4 to 126.9; Tac: 42.2 to 118.8; MMF: 74.2 to 117.3). Lipid metabolism was not significantly disturbed among children after liver transplantation, an observation that does not point to a high risk of atherogenesis. CsA seems to have the strongest untoward effect on cholesterol metabolism. Decreased GSH concentration after liver transplantation may be related to slightly impaired liver function, but GPx activity and vitamin E concentrations remained normal.
Wierzbicka
A
A
Children's Memorial Health Institute, Al. Dzieci Polskich 20, Warsaw, Poland.
Pawłowska
J
J
Socha
P
P
Jankowska
I
I
Skorupa
E
E
Teisseyre
M
M
Ismail
H
H
Czubkowski
P
P
Socha
J
J
D000975:Antioxidants / Q000378:metabolism*; D050197:Atherosclerosis / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use; D004040:Dietary Carbohydrates / Q000378:metabolism*; D004041:Dietary Fats / Q000378:metabolism*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005978:Glutathione / Q000097:blood; D005979:Glutathione Peroxidase / Q000097:blood; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008074:Lipoproteins / Q000097:blood; D016031:Liver Transplantation / Q000502:physiology*; D011183:Postoperative Complications / Q000453:epidemiology; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors
D000975:Antioxidants; D004040:Dietary Carbohydrates; D004041:Dietary Fats; D007166:Immunosuppressive Agents; D008074:Lipoproteins; D016572:Cyclosporine; D005979:Glutathione Peroxidase; D005978:Glutathione; D016559:Tacrolimus